Logo

American Heart Association

  46
  0


Final ID: MP1870

Plasma Protein N-Glycosylation Profiles Are Associated with Future Cardiovascular Events: Analyses from the JUPITER and TNT Trials

Abstract Body (Do not enter title and authors here): Background: Glycosylation—a key post-translational modification—plays a critical role in biological pathways of atherosclerosis. We previously demonstrated associations between N-glycosylation of immunoglobulin G and cardiovascular disease (CVD). However, the relationship between N-glycosylation of other plasma proteins and CVD remains largely unexplored.
Methods: We analyzed N-glycosylation of baseline plasma proteins using ultra-high-performance liquid chromatography in two nested case-control studies of incident CVD: JUPITER (NCT00239681; 513 pairs; primary prevention) and TNT (NCT00327691; 436 pairs; secondary prevention). We used conditional logistic regression to evaluate associations between 39 measured chromatographic N-glycan peaks (GP1-39) and incident CVD. The fully adjusted model accounted for age, sex, race, LDL, HDL, hypertension, diabetes, smoking, hs-CRP, BMI, aspirin use, and treatment assignment. We then performed a fixed-effects meta-analysis to combine effect estimates across cohorts. Using stepwise regression, we derived a glycan score in JUPITER and validated it in TNT. We also performed Spearman correlations between N-glycans and clinical biomarkers.
Results: The meta-analysis identified specific N-glycosylation patterns independently associated with CVD. These included mono- and digalactosylated glycans with core fucose (GP5,10), a tetragalactosylated tetrasialylated glycan (GP37), and an oligomannose glycan (GP19), all inversely associated with CVD in the fully adjusted model (aHR per SD:0.80–0.90; FDR<0.05) (Figure 1).
In contrast, antennary fucosylated glycans (GP27,33,39) were positively associated with CVD in the baseline model accounted for age, sex, and treatment assignment (FDR<0.05), but these associations lost significance after adjusting for inflammatory covariates. Notably, all three antennary fucosylated structures were positively correlated with hs-CRP in both cohorts (FDR<0.05), suggesting a potential link to inflammation-mediated CVD risk.
A glycan score of seven GPs was associated with increased CVD risk in JUPITER (aHR per SD:1.91; 95%CI:1.59–2.30; P<0.001), independent of other risk factors, and validated in TNT (P=0.03). It improved the AUC from 0.73 to 0.76 in JUPITER (P<0.001) and from 0.66 to 0.67 in TNT (P=0.03).
Conclusion: Specific N-glycosylation profiles of plasma proteins are associated with future CVD events. Furthermore, a composite glycan score enhanced CVD risk prediction beyond established risk factors.
  • Ammar, Mohammed  ( Harvard Medical School , Boston , Massachusetts , United States )
  • Demler, Olga  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Mora, Samia  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Hoshi, Rosangela  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Yazdani, Azam  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Trbojevic-akmacic, Irena  ( Genos Ltd , Zagreb , Croatia )
  • Glynn, Robert  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Giulianini, Franco  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Ridker, Paul  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Cummings, Richard  ( Beth Israel Deaconess Medical Center , BOSTON , Massachusetts , United States )
  • Lauc, Gordan  ( Genos Ltd , Zagreb , Croatia )
  • Author Disclosures:
    Mohammed Ammar: DO NOT have relevant financial relationships | Olga Demler: No Answer | Samia Mora: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Co-Inventor on Pending Patent Application: Method for prediction of future cardiovascular disease (Genos, Inc):Expected (by end of conference) ; Other (please indicate in the box next to the company name):Co-inventor on Issued Patent: Methods and systems for predicting colorectal cancer incidence and mortality, issued to LabCorp, Inc:Active (exists now) | Rosangela Hoshi: DO NOT have relevant financial relationships | Azam Yazdani: No Answer | Irena Trbojevic-Akmacic: No Answer | Robert Glynn: No Answer | Franco Giulianini: DO NOT have relevant financial relationships | Paul Ridker: No Answer | Richard Cummings: DO NOT have relevant financial relationships | Gordan Lauc: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Vascular Inflammation and Resolution

Sunday, 11/09/2025 , 09:15AM - 10:25AM

Moderated Digital Poster Session

More abstracts on this topic:
A DHX38 Spliceosomal Mutation Impairs MYC Signaling, Cardiac Transcriptome Splicing, and Leads to Diastolic Dysfunction

Iwanski Jessika, Sarvagalla Sailu, Methawasin Mei, Van Den Berg Marloes, Churko Jared

Apolipoprotein A-I Proteoforms, Cardiometabolic Status, and Coronary Heart Disease: Insights from the Dallas Heart Study

Gangwar Anamika, Des Soye Benjamin, Saldanha Suzanne, Jaiswal Shailesh, Patel Parthvi Bharatkumar, Shah Amil, Pandey Ambarish, Wilkins John, Rohatgi Anand

More abstracts from these authors:
Discussant: YELLOW III

Mora Samia, Kramer Christopher

Inflammatory proteomic signatures of metabolically unhealthy obesity

Wang Cong, Tobias Deirdre, Yazdani Azam, Demler Olga, Giovannucci Edward, Zhang Xuehong, Hazra Aditi, Leboff Meryl, Sesso Howard, Manson Joann

You have to be authorized to contact abstract author. Please, Login
Not Available